Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in ItalyCamillo Porta, Mei Sheng Duh, Chiara Paglino et al.|BMC Cancer|2011Cited by 36
Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma (LBCL)Loretta J. Nastoupil, Christopher R. Flowers, Clark R. Andersen et al.|Blood|2023Cited by 7
Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell LymphomaLoretta J. Nastoupil, Christopher R. Flowers, Clark R. Andersen et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 6
Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group.Marie-France Savard, Daniel Yick Chin Heng, Mei Sheng Duh et al.|Journal of Clinical Oncology|2019Cited by 1
Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).Audreylie Lemelin, Daniel Yick Chin Heng, Matthew Scott Ernst et al.|Journal of Clinical Oncology|2023Cited by 0